Skip to main content

Loading market data...

GKOS

Glaukos Corporation

NYSE • United states

$173.43

+$6.47

(+3.88%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Glaukos Corporation (GKOS)

Unavailable

Quotes may be delayed

$10.23B

Market Cap

608,402

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Glaukos Corporation Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 1 GLAUKOS WAY, ALISO VIEJO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

3 Aug 2026

Glaukos Corporation reported Regulation FD disclosure

Glaukos Corporation filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.

30 Jul 2026

Glaukos Corporation filed Form 10-Q

Glaukos Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Glaukos Corporation reported Operating or financial results

Glaukos Corporation filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

4 Jun 2026

Glaukos Corporation reported Shareholder voting results

Glaukos Corporation filed an 8-K covering shareholder voting results.

15 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Glaukos Corporation.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$114.49M

Total assets (USD)$920.52M

Total liabilities (USD)$238.04M

Shareholders' equity (USD)$682.49M

Long-term debt (USD)$3.04M

Debt due within a year (USD)$3.04M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$185.61M	−$17.27M	−$18.38M	−$0.31	10-Q · 29 Jul 2026
Q1 2026	$150.57M	−$19.86M	−$19.78M	−$0.34	10-Q · 30 Apr 2026
Q4 2025	$143.12M	−$139.87M	−$133.66M	Unavailable	10-K · 23 Feb 2026
Q3 2025	$133.54M	−$16.37M	−$16.23M	−$0.28	10-Q · 31 Oct 2025
Q2 2025	$124.12M	−$22.69M	−$19.66M	−$0.34	10-Q · 4 Aug 2025
Q1 2025	$106.66M	−$20.68M	−$18.15M	−$0.32	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $197.58

13.9% upside potential

📈

Strong Buy

Unavailable

👍

Buy

12

⏸️

Hold

1

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 10:47 UTC Targets range 172.00–225.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

5

Oct 2026

Navratil Tomas

CHIEF DEVELOPMENT OFFICER

Open-market sale

$164.45 per share

1,527 shares

25

Sep 2026

Navratil Tomas

CHIEF DEVELOPMENT OFFICER

Open-market sale

$154.28 per share

1,615 shares

16

Sep 2026

Navratil Tomas

CHIEF DEVELOPMENT OFFICER

Open-market sale

$166.92 per share

1,457 shares

28

Aug 2026

Navratil Tomas

CHIEF DEVELOPMENT OFFICER

Open-market sale

$180.67 per share

13,744 shares

19

Aug 2026

Kliman Gilbert H

Director

Option exercise

$25.77 per share

2,500 shares

19

Aug 2026

Kliman Gilbert H

Director

Open-market sale

$190.00 per share

2,500 shares

11

Aug 2026

Gilliam Joseph E

PRESIDENT & COO

Option exercise

$52.94 per share

60,000 shares

11

Aug 2026

Gilliam Joseph E

PRESIDENT & COO

Open-market sale

$179.74 per share

60,000 shares

7

Aug 2026

Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER

Option exercise

$33.81 per share

20,000 shares

7

Aug 2026

Thurman Alex R.

SVP & CHIEF FINANCIAL OFFICER

Open-market sale

$180.13 per share

20,000 shares

Top Shareholders

Blackrock, Inc.

9,540,056 shares

4.951% change

6/30/2026

Vanguard Group Inc

6,020,492 shares

-0.43% change

12/31/2025

Janus Henderson Group Ltd.

5,348,395 shares

77.17% change

3/31/2026

Jupiter Topco Llc

4,862,894 shares

New% change

6/30/2026

Vanguard Portfolio Management Llc

3,321,839 shares

3.537% change

6/30/2026

Primecap Management Co/Ca/

3,040,705 shares

-9.788% change

6/30/2026

Vanguard Capital Management Llc

2,551,132 shares

1.689% change

6/30/2026

State Street Corp

2,315,568 shares

6.091% change

6/30/2026

Millennium Management Llc

1,581,016 shares

34.704% change

6/30/2026

Holocene Advisors, Lp

1,514,931 shares

9.483% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 10:47 UTC· 19 hours ago

Research coverage and investment tools

Glaukos Corporation (GKOS) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Medical/Dental Instruments). Its last price was US$173.43 on 20 Oct 2026. That is 85% of the way from its 52-week low of US$73.16 to its 52-week high of US$191.62. Its market capitalisation was US$10.23 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$185.61M	−$17.27M	−$18.38M	−$0.31	81.7%	-9.3%	$12.09M	10-Q · 29 Jul 2026 (opens in a new tab)
Q1 2026	$150.57M	−$19.86M	−$19.78M	−$0.34	77.9%	-13.2%	−$16.49M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$143.12M	−$139.87M	−$133.66M	Unavailable	-1.1%	-97.7%	$3.93M	10-K · 23 Feb 2026 (opens in a new tab)
Q3 2025	$133.54M	−$16.37M	−$16.23M	−$0.28	78.4%	-12.3%	−$11.73M	10-Q · 31 Oct 2025 (opens in a new tab)
Q2 2025	$124.12M	−$22.69M	−$19.66M	−$0.34	78.3%	-18.3%	$5.80M	10-Q · 4 Aug 2025 (opens in a new tab)
Q1 2025	$106.66M	−$20.68M	−$18.15M	−$0.32	77.2%	-19.4%	−$20.46M	10-Q · 1 May 2025 (opens in a new tab)

Cash and equivalents: $114.49M
Total assets: $920.52M
Total liabilities: $238.04M
Shareholders' equity: $682.49M
Long-term debt: $3.04M
Debt due within a year: $3.04M

8-K · 3 Aug 2026

Glaukos Corporation reported Regulation FD disclosure (opens in a new tab)

Glaukos Corporation filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.
10-Q · 30 Jul 2026

Glaukos Corporation filed Form 10-Q (opens in a new tab)

Glaukos Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 30 Jul 2026

Glaukos Corporation reported Operating or financial results (opens in a new tab)

Glaukos Corporation filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.
8-K · 4 Jun 2026

Glaukos Corporation reported Shareholder voting results (opens in a new tab)

Glaukos Corporation filed an 8-K covering shareholder voting results.
SCHEDULE 13G/A · 15 May 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Glaukos Corporation.

Insider	Date	Transaction	Shares	Average price	Filing
Navratil Tomas CHIEF DEVELOPMENT OFFICER	5 Oct 2026	Open-market sale (S)	−1,527	$164.45	Form 4 (opens in a new tab)
Navratil Tomas CHIEF DEVELOPMENT OFFICER	25 Sep 2026	Open-market sale (S)	−1,615	$154.28	Form 4 (opens in a new tab)
Navratil Tomas CHIEF DEVELOPMENT OFFICER	16 Sep 2026	Open-market sale (S)	−1,457	$166.92	Form 4 (opens in a new tab)
Navratil Tomas CHIEF DEVELOPMENT OFFICER	28 Aug 2026	Open-market sale (S)	−13,744	$180.67	Form 4 (opens in a new tab)
Kliman Gilbert H Director	19 Aug 2026	Option exercise (M)	+2,500	$25.77	Form 4 (opens in a new tab)
Kliman Gilbert H Director	19 Aug 2026	Open-market sale (S)	−2,500	$190.00	Form 4 (opens in a new tab)
Gilliam Joseph E PRESIDENT & COO	11 Aug 2026	Option exercise (M)	+60,000	$52.94	Form 4 (opens in a new tab)
Gilliam Joseph E PRESIDENT & COO	11 Aug 2026	Open-market sale (S)	−60,000	$179.74	Form 4 (opens in a new tab)
Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER	7 Aug 2026	Option exercise (M)	+20,000	$33.81	Form 4 (opens in a new tab)
Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER	7 Aug 2026	Open-market sale (S)	−20,000	$180.13	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	9,540,056	4.951%
Vanguard Group Inc	12/31/2025	6,020,492	-0.43%
Janus Henderson Group Ltd.	3/31/2026	5,348,395	77.17%
Jupiter Topco Llc	6/30/2026	4,862,894	New
Vanguard Portfolio Management Llc	6/30/2026	3,321,839	3.537%
Primecap Management Co/Ca/	6/30/2026	3,040,705	-9.788%
Vanguard Capital Management Llc	6/30/2026	2,551,132	1.689%
State Street Corp	6/30/2026	2,315,568	6.091%
Millennium Management Llc	6/30/2026	1,581,016	34.704%
Holocene Advisors, Lp	6/30/2026	1,514,931	9.483%

Previous close: 166.96 USD
Day range: 168.00 – 176.06 USD
52-week range: 73.16 – 191.62 USD
Volume: 608,402
Market cap: $10.23B
Average volume: 616,945
EPS (FY 2025, diluted): −3.28 USD
Shares outstanding: 58.98M
Beta (5Y monthly): 0.75

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:10 UTC· 23 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for GKOS yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.